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Summary
Fragile-X syndrome is a trinucleotide-repeat–expansion
disorder in which the clinical phenotype is believed to
result from transcriptional silencing of the fragile-X
mental retardation 1 (FMR1) gene as the number of
CGG repeats exceeds ∼200. For premutation alleles
(∼55–200 repeats), no abnormalities in FMR1-gene ex-
pression have been described, despite growing evidence
of clinical involvement in premutation carriers. To ad-
dress this (apparent) paradox, we have determined, for
16 carrier males (55–192 repeats), the relative levels of
leukocyte FMR1 mRNA, by use of automated fluores-
cence-detection reverse transcriptase–PCR, and the per-
cent of lymphocytes that are immunoreactive for FMR1
protein (FMRP). For some alleles with 1100 repeats,
there was a reduction in the number of FMRP-positive
cells. Unexpectedly, FMR1 mRNA levels were elevated
at least fivefold within this same range. No significant
increase in FMR1 mRNA stability was observed in a
lymphoblastoid cell line (160 repeats) derived from one
of the carrier males, suggesting that the increased mes-
sage levels are due to an increased rate of transcription.
Current results support a mechanism of involvement in
premutation carriers, in which reduced translational ef-
ficiency is at least partially compensated through in-
creased transcriptional activity. Thus, diminished trans-
lational efficiency may be important throughout much
of the premutation range, with a mechanistic switch oc-
curring in the full-mutation range as the FMR1 gene is
silenced.
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Introduction
In fragile-X syndrome (MIM 309550), clinical involve-
ment is thought to be the result of reduced levels of the
normal protein product of the fragile-X mental retar-
dation 1 (FMR1) gene. In the standard model of FMR1
expression, protein levels are reduced as a direct con-
sequence of transcriptional silencing of the FMR1 gene,
which occurs when it becomes fully expanded (1∼200
CGG repeats; full mutation) and methylated (Pieretti et
al. 1991). In accord with this model, nearly all males
with methylated, full-mutation alleles have mental re-
tardation and have little (!10% of normal) or no FMR1
protein (FMRP) in the peripheral lymphocytes (Willem-
sen et al. 1997; Tassone et al. 1999). Modest FMRP
levels can occur in individuals who have fully expanded
alleles with a partial or complete lack of methylation,
or they can occur as a consequence of somatic mosai-
cism, in which some cells harbor alleles with !200 re-
peats. Individuals with higher FMRP levels usually pre-
sent with a milder clinical phenotype, with learning
disabilities occurring in the absence of mental retarda-
tion (Smeets et al. 1995; de Vries et al. 1996; Hagerman
1996; Tassone et al. 1999).
For those individuals with CGG-repeat numbers in
the range of ∼55–200, the term “premutation” has been
coined, to reflect both the propensity for allele expansion
in subsequent generations and the absence of direct clin-
ical involvement (Fu et al. 1991; Oberle` et al. 1991).
The findings of most clinical investigations of individ-
uals—mainly females—with premutation alleles have
demonstrated that the individuals have normal intellec-
tual abilities (Mazzocco et al. 1993; Reiss et al. 1993;
Rousseau et al. 1994). However, a limited number of
females with the premutation do have mild physical and/
or emotional problems (Franke et al. 1998; Riddle et al.
1998). Males with the premutation have also been char-
acterized, and the results of several studies have dem-
onstrated that at least some males have cognitive im-
pairments (Loesch et al. 1987, 1994; Dorn et al. 1994;
Rousseau et al. 1994; Smits et al. 1994; Hagerman et
al. 1996; Steyaert et al. 1996). Findings of clinical in-
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volvement in the premutation range suggest the need to
reexamine the standard model—and the concept of the
premutation—at the molecular level.
Expression of the FMR1 gene has not been investi-
gated, in a systematic fashion, for alleles in the pre-
mutation size range. FMR1 mRNA and FMRP levels
were reported to be normal in lymphocytes and in cul-
tured lymphoblastoid and fibroblast cell lines from in-
dividual carriers of a premutation (Pieretti et al. 1991;
Devys et al. 1993; Feng et al. 1995a, 1995b; Hmadcha
et al. 1998). Barring the possibility of occult expansion
in other tissues, these latter observations present an ap-
parent paradox for the standard model, since clinical
involvement in some males and females with premuta-
tion alleles leads to the expectation of reduced FMR1
mRNA and/or FMRP levels. To examine this issue, we
have employed a quantitative-fluorescence reverse tran-
scriptase–PCR (RT-PCR) method (Livak et al. 1995;
Heid et al. 1996), to obtain precise estimates of FMR1
mRNA levels in peripheral blood leukocytes. This
method employs a dual-labeled, fluorogenic hybridiza-
tion probe, to provide accurate and reproducible quan-
tification of mRNA levels. Quite unexpectedly, for pre-
mutation alleles in the 100–200-repeat range, FMR1
message levels are approximately fivefold higher than
the levels found in normal individuals. These elevated
mRNA levels are present even in the face of lowered
percentages of FMRP-positive (FMRP[]) lymphocytes
in this repeat range. Our observations suggest that mech-
anisms other than reduced transcription (e.g., blocks in
nuclear export or translation) are responsible for the
FMRP deficit and, ultimately, for clinical involvement in
the premutation range.
Material and Methods
Isolation and Analysis of Genomic DNA
Genomic DNA was isolated from peripheral blood
leukocytes that were derived from 3–5 ml of blood ob-
tained from carrier males or normal controls and from
lymphoblastoid cell lines. This research was performed
with protocols approved by the local institutional review
board and with signed, informed consent. DNA isolation
employed Puregene kits (Gentra). Southern blot analyses
were performed for all carrier males, as described else-
where (Taylor et al. 1994). For each analysis, 5 mg DNA
were digested with the use of EcoRI and NruI; this was
followed by electrophoresis in 1% agarose/Tris-acetate
gels and by transfer to nylon membranes. Blots were
hybridized with the FMR1-specific probe StB12.3 (Ob-
erle` et al. 1991). Standard PCR analysis was also used
to determine the number of CGG repeats in carrier
males, by use of primers “1” and “3,” as described else-
where (Brown et al. 1993). Of the 16 males with CGG-
expansion (premutation) alleles represented in the pre-
sent investigation, 9 possess alleles within the
55–100-repeat range (n = 55, 58, 60, 66, 73, 81, 84,
85, and 94), and 7 possess alleles within the 100–200-
repeat range (CGG)n, n = 113, 126, 130, 133, 180,
183, and 190); the plus sign () designates a smear of
unmethylated alleles extending from 180 to 280 repeats,
on the basis of the results of a Southern blot. The afore-
mentioned groups were compared with eight control in-
dividuals with alleles within the normal repeat range (n
= 25, 28, 29, 30, 35, 39, 44, and 54).
Total-RNA Isolation and cDNA Synthesis
Total cellular RNA was prepared from 3–5 ml of
blood, by use of standard methods (Purescript kits [Gen-
tra]; Trizol [BRL]), and was quantified by total absorb-
ance at 260 nm. RT reactions were performed in 100-
ml aliquots containing 1 # PCR buffer (20 mM Tris-
HCl, pH 8.4, 50 mM KCl) (Gibco/BRL), 5.5 mM MgCl2,
1 mM each dNTP, 5 mM random sequence deoxyoli-
gonucleotide hexamers (Gibco/BRL), 0.4 U RNAse in-
hibitor (Gibco/BRL), and 2.5 U Moloney murine leu-
kemia-virus RT (Gibco/BRL). At least three concen-
trations of total RNA (500 ng, 250 ng, and 125 ng, per
100-ml reaction) were used for each sample, to ensure
linearity of the RT-PCR response. The RT temperature
profile was as follows: 25C for 10 min, 48C for 40
min, 95C for 5 min, and final cooling to 4C. As a
control for genomic contamination, 500 ng total RNA
were treated as described above, with the exception that
the RT was omitted.
Quantitative Fluorescence PCR for Determination of
Relative FMR1 mRNA Levels
Fluorescence PCR reactions were performed with the
use of the 7700 Sequence Detector (PE Biosystems) (Li-
vak et al. 1995; Heid et al. 1996). The instrument de-
termines relative abundances of mRNA, by use of real-
time fluorescence detection of dual-labeled (TaqMan)
probes, 5′-FAM (6-carboxyfluorescein)-deoxyoligonu-
cleotide-TAMRA (6-carboxytetramethylrhodamine)-3′
(PE Biosystems), which are complementary to the PCR
amplicon. A passive reference dye, ROX (PE Biosystems
User Bulletin), is used to normalize all fluorescence signal
intensities. During PCR amplification, the fluorescence
intensity of the reporter dye (fFAM) is normalized to the
fluorescence intensity of the reference dye (fROX)
( ). The baseline value for Rn is deter-R { f /fn FAM ROX
mined during the first 10–15 cycles (Heid et al. 1996),
as is the standard deviation (SD) of Rn(jRn). The change
in Rn, , is directly proportional toDR ({ R  R )n n n,baseline
the number of copies of the amplicon (Gibson et al.
1996). PCR primers were synthesized from b-cyanoe-
thylphosphoramidites, by use of a Millipore Expedite
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automated synthesizer, model 8909. TaqMan probes
were obtained from Applied Biosystems/PE or Synthetic
Genetics. Cross-comparisons of quantitative-PCR re-
sults were performed with the use of at least two of three
7700 Sequence Detectors, one of which was located at
the University of California, San Francisco Cancer Cen-
ter, and two of which were located at the University of
Colorado School of Medicine. There was no instance of
a significant difference in estimated mRNA level among
the instruments.
In the present investigation, the FMR1 amplicon
is a 122-bp product that spans the junction between
exons 3 and 4 of the FMR1 gene (GenBank accession
number L29074), thus eliminating false signals resulting
from genomic contamination. The following FMR1
primer/probe set was used: forward (F) primer (F-
FMR1), 5′-GCA GAT TCC ATT TCA TGA TGT CA-
3′; reverse (R) primer (R-FMR1), 5′-ACC ACC AAC
AGC AAG GCT CT-3’; and TaqMan probe, 5′-(FAM)-
TGA TGA AGT TGA GGT GTA TTC CAG AGC AAA
TGA-(TAMRA)-3′. The relative abundance of FMR1
mRNA, as well as variations encountered during sample
preparation, was assessed by use of a reference (81-bp)
amplicon derived from b-glucoronidase (GUS) mRNA
(GenBank accession number NM000181). GUS mRNA
represents a convenient reference, since we have ob-
served that normal peripheral blood leukocytes maintain
comparable levels of FMR1 and GUS mRNAs. TheGUS
amplicon spans the junction between exons 11 and 12
of the GUS gene and utilizes the following primer/probe
set: F-GUS, 5′-CTC ATT TGG AAT TTT GCC GAT T-
3′; R-GUS, 5′-CCG AGT GAA GAT CCC CTT TTT A-
3′; and TaqMan (sense) probe, 5′-(FAM)-TGA ACA
GTC ACC GAC GAG AGT GCT GG-(TAMRA)-3′.
For each blood sample, quantitative-PCR reactions
were performed in duplicate for each starting total
RNA concentration, for both FMR1 and GUS am-
plicons (a total of 12 reactions). Control reactions
(FMR1 and GUS) were run in parallel (an additional
12 reactions), with the use of a standard lympho-
blastoid line known as “RP” (RPM 7666; normal lym-
phoblasts [ATCC CCL114]). The control reactions are
necessary for correction of potential variations in buf-
fer composition and/or pipetting errors and for cor-
rection of relative efficiencies of RT reactions. PCR
amplifications were performed in 50-ml reaction vol-
umes containing 1# PCR buffer (Applied Biosystems/
PE), 5.5 mM MgCl2, 0.1 mM each primer and probe,
200 mM each dNTP, and 0.025 U Taq Gold (Applied
Biosystems/PE)/ml. Cycle parameters were as follows:
95C for 12 min, then (95C for 15 s, 60C for 1 min)
# 50 cycles, and then a final temperature of 25C.
Data Analysis
The number of cycles required for FAM fluorescence
to reach a threshold level that is ∼10 SDs (of fluctua-
tions in background fluorescence, jRn) above the mean
background fluorescence ({Ct value) was determined
for each PCR reaction (FMR1, GUS, and RNA con-
centration), by use of 7700 automated software. Plots
of Ct versus total RNA were performed for each sam-
ple, to verify appropriate log-linear behavior ( Ct2 ∝
total RNA). For a perfect log-linear response, each cy-
cle represents one doubling of the number of amplicon
DNA molecules; thus, a DCt of 1 reflects a twofold
difference in RNA concentration. All relative FMR1
mRNA levels were determined from the following re-
lation: FMR1 mRNArel = = ,
[DC (sample)  DC (RP)] DDCt t t2 2
where DCt(sample) [ =Ct(FMR1)  Ct(GUS)] is the dif-
ference, in threshold cycle number, between FMR1 and
GUS, for a given sample and total-RNA concentration;
where DCt(RP) is the same difference for the control
cell line; and where DDCt is the cell-line–corrected dif-
ference. This approach will be discussed in more detail
below. RT-PCR amplifications were also examined, by
means of PAGE (12%), to verify the presence of the
correct amplicon. After ethidium bromide staining, sin-
gle bands were visible only at the expected positions
for the FMR1 and GUS amplicons. Furthermore, con-
trol experiments done with the use of an FMR1 deletion
(Gu et al. 1994) extending from ∼80 kb upstream of
the FMR1 gene through exon 7 (thus deleting the entire
5′ regulatory region and the [CGG]n repeat as well as
the targets of the PCR primers) did not produce de-
tectable FMR1 amplicon after 50 cycles of PCR. All
analyses of Ct data, including nonpaired t-test and re-
gression analyses, were performed on SigmaPlot (SPSS,
Inc.).
Immunocytochemistry
The percentage of lymphocytes expressing detectable
FMRP was determined by immunocytochemistry of
blood smears (Willemsen et al. 1995, 1997; Tassone et
al. 1999), with use of the anti-FMRP monoclonal an-
tibody from hybridoma clone 1C3-a (Devys et al. 1993).
The method is an indirect alkaline phosphatase–staining
technique, in which cells fixed with 3% paraformalde-
hyde and permeabilized with methanol are incubated
with FMRP-specific antibody, followed by incubation
with goat anti-mouse immunoglobulin conjugated with
biotin (DAKO) and a final incubation with streptavidin-
biotinylated alkaline phosphatase (DAKO). Visualiza-
tion of FMRP is accomplished with the use of a fuchsin-
substrate chromagen system (DAKO). For each blood
sample, 200 lymphocytes are counted, and FMRP()
lymphocytes are scored for the presence of a red-staining
cytoplasmic ring that indicates the presence of FMRP.
Cell Culture and Inhibition of Transcription
Lymphoblastoid cell lines were grown in RPMI 1640
supplemented with 12% FCS and glutamine. For deter-
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Figure 1 Outline of analysis of FMR1 mRNA levels, by use of automated, fluorescence-detection RT-PCR, with peripheral blood leukocytes
obtained from a male premutation carrier with 192 CGG repeats. A, Logarithm of the relative reporter (FAM) fluorescence intensities DRn, for
FMR1 (blackened circles) and GUS (unblackened circles) probes, plotted as a function of the cycle number (C) in the PCR reaction (total cellular
RNA 5 ng/ml). For a set of curves, Ct is the cycle number at a given threshold value of probe fluorescence (see the Material and Methods
section). DCt is the difference in cycle number for a given fluorescence threshold. B, Plots of Ct and DCt, as a function of total cellular RNA.
Ct plots: blackened triangles denote the FMR1 probe, control (RP) cell line; unblackened triangles, GUS probe, RP cell line; unblackened circles,
GUS probe, carrier male; blackened circles, FMR1 probe, carrier male. DCt plots: gray-shaded circles, , carrier male; gray-C (FMR1)C (GUS)t t
shaded triangles, , RP cell line. DDCt (blackened squares) represents the corrected value for the difference in cycle numberC (FMR1)C (GUS)t t
for FMR1 mRNA versus GUS mRNA and is used to determine relative mRNA levels (see the Material and Methods section).
mination of FMR1 mRNA stabilities, actinomycin D (10
mg/ml) was used to block transcription (Baeyens and
Cornett, 1993; Feng et al. 1995a). Lymphoblastoid cell
lines that were established, by means of Epstein-Barr
virus transformation, from normal males and carrier
males were plated at a density of cells/ml in61 # 10
50 ml media. After 24 h, actinomycin D was added, and
aliquots of suspended cells were removed at designated
times. Cells were washed in PBS, and total RNA was
isolated as described above. Samples were subjected to
fluorescence RT-PCR, which was performed as described
above.
Results
Automated Fluorescence-Detection RT-PCR as a
Quantitative, Reproducible Method for Measurement
of FMR1 mRNA Levels
We have used an automated, fluorescence-detection
RT-PCR assay to quantify the levels of FMR1 mRNA
in carrier males with CGG-expansion alleles lying
within the range of ∼55–200 repeats (premutation al-
leles). The basis of this method is the accurate deter-
mination of the increase in FMR1-specific amplicon
DNA concentration during the early (log-phase) cycles
of the PCR process. In the fluorescence-based assay,
the increase in DNA concentration is monitored by
the use of a complementary, dual-fluorophore–labeled
oligonucleotide probe (TaqMan probe), with the ex-
tent of fluorescence being directly proportional to
DNA copy number. An overview of the analysis, for
a carrier male with 192 CGG repeats, is presented in
figure 1.
In the present study, we used FMR1- and GUS-based
probes that possess a FAM reporter at the 5′ ends and
a TAMRA quencher at the 3′ ends. During the extension
phase of each PCR cycle, the FAM reporter is cleaved
from the probe, as a result of the 5′ exonuclease activity
of the polymerase, thereby resulting in an incremental
increase in fluorescence intensity. The increases in flu-
orescence DRn (see the Material and Methods section,
above) for each cycle are monitored in real time, by use
of a 7700 Sequence Detector (PE Biosystems).
Relative mRNA levels are determined by a compari-
son of the cycle numbers for which the relative fluores-
cence signal, DRn, exceeds the threshold value (threshold
cycle number is designated “Ct” (see the Material and
Methods section above). The precise value of the thresh-
old fluorescence is not critical, provided that it lies in
the log-phase region. For example, for the carrier male
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Table 1
Relative FMR1 mRNA Levels in Peripheral Blood Leukocytes of Males with
Premutation Alleles
FMR1 mRNA LEVELS (MEAN  SD)
CGG REPEAT (n)a SAMPLE SIZEb RELATIVE TO GUSc
RELATIVE TO
nl Sample Mean
100 ! n ! 200 (hp) 7 (14) 7.21  .63 (7.15  .47) 5.1  .68
55 ! n ! 100 (lp) 9 (14) 2.44  .32 (2.75  .25) 1.7  .41
n ! 55 (nl)d 8 1.42  .25 1.00
a Groupings represent all individuals with alleles (CGG)n in the designated size range.
b Sample sizes in parentheses include repeat analyses of RNA of some individuals
within the group. Results of repeat analyses are averaged but are otherwise unweighted
for the smaller numbers.
c All FMR1 mRNA levels relative to GUS are normalized to the level of FMR1mRNA
relative to GUS in a reference cell line (RPM 7666), as described in the Material and
Methods section. Numbers in parentheses include repeat analyses, as specified above
(see footnote b).
d Normal control individuals include females; there is no significant difference, in
FMR1 mRNA levels, between males and females in this range.
(192 CGG repeats) represented in figure 1A, the DCt
value of 1.750 , de-[= C (FMR1 ) C (GUS )]t carrier t carrier
termined at , differs, by only ∼1%, from theDR = 0.01n
value determined at a 10-fold-higher fluorescence thresh-
old level (DCt = 1.734, at ); note, however,DR = 0.1n
that the threshold level must be held constant for any
given comparison. For all of the samples analyzed in the
current investigation, Ct values fall within the range of
∼25–30. Within this range, all samples display the ex-
pected log-linear dependence of Ct on total cellular RNA
concentration.
Although blood samples are routinely processed !24
h after the blood draw, delays are sometimes encoun-
tered during transportation of the sample. We have in-
vestigated the influence of delayed RNA extraction, by
isolating RNA, at various times, from aliquots of blood
(stored at 4C) obtained from a carrier female. For ex-
tractions performed 0, 2, 5, and 7 d postdraw, no re-
duction in either FMR1 or GUS mRNAs was observed.
In addition, we generally see no significant variation in
FMR1 mRNA levels for either normal individuals or
individuals with premutations who have had blood
drawn on more than one occasion.
Sets of replicate RT-PCR experiments for each
blood sample are always accompanied by equivalent
sets of reference measurements for the lymphoblastoid
cell line (RPM 7666 [RP]; see the Material and Meth-
ods section above). The DCt values determined for
each blood sample (DCt,sample) are normalized to the
corresponding DCt values for the cell line (DCt,RP);
thus, DDCt,sample = DCt,sample  DCt,RP. This latter cor-
rection takes into account batch-to-batch variations
in Taq polymerase, probe and/or primer efficiency,
and variations in RT efficiency. This approach thus
allows one to directly compare data generated in dif-
ferent experiments and reduces experimental uncer-
tainty in relative mRNA levels. Failure to correct for
such variation in RT-PCR experiments would severely
degrade the precision of experimental comparisons of
mRNA concentration. A second procedure—namely,
an analysis of the concentration dependence of the Ct
and DCt values (fig. 1B)—is also performed for each
sample and cell line control. Strong variation in DCt
may indicate problems with pipetting; such experi-
ments can be repeated.
Significant Elevation of FMR1 mRNA Levels in Carrier
Males
We have determined the relative FMR1 mRNA levels
for 16 carrier males, by means of the fluorescence-based
RT-PCR approach. Nine males possess alleles with a
range of 55–100 repeats (designated as “low premuta-
tion” [lp]), and 7 possess alleles with a range of
∼100–200 repeats (designated as “high premutation”
[hp]) (for allele sizes, see the Material and Methods sec-
tion above). Longer exposures (3–5 d) of Southern blots
were performed, to eliminate the possible presence of
methylated alleles. Note that one member of this latter
group (180; see the Material and Methods section
above) possesses a smear of allele sizes that extends from
180 repeats into the low full-mutation range (280 re-
peats). Because all of his alleles were unmethylated,
which is typical of a premutation, his mRNA data were
included. Allele sizes were determined by conventional
PCR analysis, which was augmented in some instances
by Southern gel analysis. These groups were compared
with a group of eight normal control individuals. The
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Table 2
Analysis of Significance for the Differences in
FMR1 mRNA Levels among Three Allele Ranges
(Nonpaired t-Test)
Comparisona Pb
hp 7 (14) vs. lp 9 (14) 4.3 # 106 (1.2 # 108)
hp 7 (14) vs. nl 8 6.5 # 107 (3.3 # 108)
lp 9 (14) vs. nl 8 2.5 # 102 (2.5 # 103)
a Sample groupings are as in table 1.
b Derived from nonpaired t-tests. Numbers out-
side the parentheses are based on unweighted aver-
ages of repeat measurements for individuals within
each group (see table 1).
Figure 2 Plot of FMR1 mRNA levels (relative to GUS mRNA
[rel]), as a function of the CGG repeat number (n). nl, , lp =n ! 55
, and hp = . Horizontal lines rep-55  n ! 100 100  n  200
resent the group (unweighted) means from table 1.
relative FMR1 mRNA levels for these three groups are
presented in table 1; an analysis of the significance of
the differences reported for these three groups is pre-
sented in table 2. The relative FMR1 mRNA levels for
each individual are presented in figure 2.
It is evident, from the data presented in table 2, that
FMR1 mRNA levels are elevated in both subgroups of
carrier males, relative to those in the normal control
population. Moreover, there is a substantial (fivefold)
elevation in the upper portion (hp) of the premutation
range relative to the lower portion (lp). We recognize
that the boundary between hp and lp (100 CGG repeats)
is somewhat arbitrary in the absence of an underlying
mechanistic basis; however, it does serve to underscore
the growth in relative mRNA levels as one approaches
the upper portion of the premutation range. Moreover,
the current division yields a more conservative estimate
for the increases in FMR1 mRNA than do regression
analyses (see the Discussion section, below). Also sig-
nificant is the fact that, in our limited group, we have
not observed any hp males with FMR1 mRNA levels in
the normal range. No FMR1 mRNA was detected, after
50 PCR cycles, for a male with an FMR1 deletion (Gu
et al. 1994) that encompasses the 5′ portion of the FMR1
gene. Finally, the absence of any reduction in GUS
mRNA levels in hp samples relative to the levels in nl
samples (data not shown) rules out general suppression
of GUS in carrier leukocytes.
mRNA Decay Experiments as Evidence That the
Elevated FMR1 mRNA Levels Are Not a Result of
Increased mRNA Stability
To determine whether the increased FMR1 mRNA
levels are due to increased mRNA stability in carrier
males, we have estimated the half-lives ( values) for the1t
2
decay of both FMR1 and GUS mRNAs from an EBV-
transformed lymphoblastoid line MM, derived from the
carrier male with 183 CGG repeats. DNA analysis of
the transformed cell line indicated a small reduction in
repeat number (to 160 repeats). A second line
(AG09391, “AG”; NIA Cell Repository) was used as a
normal control. After treatment of cells in culture with
the RNA polymerase II inhibitor actinomycin D (10 mg/
ml), mRNA levels were measured, over time, by use of
the fluorescence-based RT-PCR method. The results of
this analysis are presented in figure 3 and in table 3. The
absence of any significant increase in FMR1 half-life in
the premutation cell line, coupled with the approxi-
mately eightfold increase in mRNA level, indicates that
increased stability cannot account for the higher mRNA
level. This observation implies that the increase in FMR1
mRNA levels in the carrier males is the result of an
increased rate of mRNA production.
Immunocytochemical Staining as Revealing a Reduced
Percentage of FMRP() Lymphocytes in Carrier Males
with hp Alleles (100–200 CGG Repeats)
Production of FMRP is generally thought to be normal
in the premutation range (Devys et al. 1993; Verheij et
al. 1993; Feng et al. 1995a; Kaufmann et al. 1999; Tas-
sone et al. 1999), although we have recently observed
reduced fractions of FMRP() cells in three males with
premutations with hp alleles (Tassone et al., in press).
In two of the males, reduced FMRP production was also
observed by western blot analysis (Hagerman et al.
1996; D. Nelson, personal communication). We have
used the immunocytochemical staining method (Willem-
sen et al. 1995, 1997) to determine the percentage of
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Figure 3 Plots of the increase in Ct values for FMR1 and GUS
mRNAs, as a function of time after treatment of cell lines with 10 mg
actinomycin D/ml. FMR1 (blackened symbols) and GUS (unblackened
symbols) probes indicate results for both a normal control cell line,
AG (squares), and a premutation cell line, MM (160 CGG repeats)
(circles). Increasing Ct reflects decreasing mRNA level, with an increase
of one unit representing a twofold decrease in probe-specific message.
Figure 4 Plot of %FMRP() lymphocytes, as a function of
CGG-repeat number. The standard error associated with each point
is ∼4%. The horizontal dotted line represents 1 SD below the mean
value of the %FMRP() lymphocytes for males with nonexpanded
alleles (Willemsen et al. 1997); dashed lines, 99% confidence limits
for a second-order regression of the current data.
FMRP() lymphocytes from several additional hp car-
rier males. On the basis of previous estimates of the
fraction of FMRP() lymphocytes from 33 males with
nonexpanded alleles ( ) (Willemsen et al.89% 9%
1997; also see Tassone et al. 1999), males with allele
sizes that have a range of 100–200 repeats (fig. 4) appear
to have reduced FMRP-protein expression. It should be
noted that positive staining for FMRP does not directly
report cellular levels of FMRP; rather, it reflects the pres-
ence of a threshold level of FMRP in each lymphocyte.
Therefore, the results presented in figure 4 are inter-
preted simply as a reflection of reduced FMRP produc-
tion in hp-carrier males.
Discussion
In the present study, we have demonstrated that males
who are fragile-X carriers maintain substantially higher
levels of FMR1 message in peripheral blood leukocytes
than do normal control individuals. Moreover, the mag-
nitude of the increase appears to be approximately five-
fold greater for larger alleles (∼100–200 CGG repeats).
Although our sample size is relatively limited, the in-
crease is highly significant (table 2); we have not ob-
served any males with alleles in that size range whose
FMR1 mRNA levels are not increased. Therefore, the
current data establish the presence of an FMR1-specific,
(molecular) phenotypic abnormality in males with alleles
in the premutation size range.
There have been several previous reports of FMR1
mRNA levels in the premutation range (Pieretti et al.
1991; Devys et al. 1993; Feng et al. 1995a, 1995b;
Hmadcha et al. 1998). Pieretti et al. (1991) reported
normal RNA levels in 10 females with premutations;
however, no allele sizes were reported. Devys et al.
(1993) reported normal mRNA levels in three lympho-
blastoid lines with CGG repeats in the 90–100 range.
Similar results were reported, by Feng et al. (1995a), for
several lymphoblastoid lines with CGG repeats in the
84–104 range and, by Hmadcha et al. (1998), for a
premutation male (leukocytes) with 101 repeats. These
latter results are qualitatively consistent with the current
results for the lp group, which show only a modest in-
crease in mRNA level. Feng et al. (1995b) presented
RNAse protection results for subcloned fibroblast cell
lines from a single male with mosaicism. The relative
FMR1 mRNA levels were not reported for individual
alleles within the premutation range, although the av-
erage mRNA level for all expanded alleles was stated to
be only slightly (albeit not significantly) elevated, com-
pared with the levels seen for normal alleles. It should
be noted, however, that the average was taken over both
premutation (lp and hp) and full-mutation alleles. Thus,
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Table 3
Linear-Regression Analysis of Decay of FMR1 and GUS mRNAs in
Lymphoblastoid Cell Lines after Treatment with Actinomycin D
Cell Linea bDC (0)t
c1t (FMR1)
2
1t (GUS)
2
1 1t (FMR1)/t (GUS)
2 2
MM (CGG160) 1.3 8.8 h 9.4 h .94
AG09391 1.8 7.7 8.3 .93
NOTE.—First-order regression analyses were performed on each of
the decay profiles in figure 3, by use of the following functional form:
.1C = C (0) (1/t )# t(h)t t 2
a As described in the text.
b Values for each cell line were determined, from the Y-intercepts
of first-order regression analyses of the FMR1 and GUS mRNA decay
curves, as the difference of the intercepts; thus, DC (0) = C (0) t t FMR1
. , mRNArel(FMR1, MM) = 8.6, whereC (0) DDC = 3.1 DDC (0) =t GUS t t
and relative FMR1 mRNA = .DDC (0)tDC (0)  DC (0) 2t MM t AG
c Decay half-lives ( ) are given by the reciprocal of the slopes of1t
2
for each curve.C (t)t
it is difficult to make an allele-specific comparison of the
results of the present study and those of the study by
Feng et al. (1995b). Finally, it should be noted that the
results of previous studies did not report controls for
concentration dependence; such experiments are difficult
to perform with the use of RNAse protection or gel-
based RT-PCR methods. The ability to perform multiple
control experiments represents a singular advantage of
the automated method—one that we have found to be
necessary for the accurate quantification of relative
FMR1 mRNA levels.
The current observations are particularly germane
to the phenotypic status of males with premutations,
since recognition of clinical involvement in this range
is inconstant. Variation in reported prevalences of
clinical involvement is due, in part, to the definition
of involvement. In some studies, the definition is lim-
ited to cognitive impairment, whereas, in others, both
cognitive and behavioral abnormalities are recognized
(Dorn et al. 1994; Loesch et al. 1994; Hagerman et
al. 1996; Franke et al. 1998; reviewed in Hagerman
1999). Furthermore, for at least some apparent car-
riers, cognitive and/or behavioral involvement may be
the result of conditions unrelated to fragile-X syn-
drome (Hagerman 1999; Tassone et al., in press).
Therefore, the observation of increased FMR1 mRNA
levels in males with premutations, apparent even for
alleles with !100 repeats, establishes the presence of
an abnormal, FMR1-specific molecular phenotype in
the premutation range. The present observations pro-
vide a possible molecular foundation for the clinical
observations in the premutation range, although the
mechanistic linkage is not yet understood.
It is also interesting to speculate as to whether the
elevated mRNA levels may give rise to a clinical phe-
notype that is unique to the premutation range. Al-
though the current work has focused on carrier males,
there is evidence, in a subgroup of carrier females, of a
unique phenotype that includes premature menopause
and a higher rate of twinning, which are features unob-
served in females with the full mutation (Turner et al.
1994; Murray et al. 1998; Allingham-Hawkins et al.
1999). This issue is currently under investigation; how-
ever, the levels of FMR1 mRNA in premutation females
are likely to be influenced by the activation ratio.
An immunocytochemical approach has been used to
identify the percentage of cell populations in which re-
duced levels of FMRP are expressed (Willemsen et al.
1995, 1997). Although this approach is not particularly
sensitive to mild reductions in the FMRP level, we do
observe, for the larger alleles within the premutation
range, significant reductions in the percentages of
FMRP() lymphocytes (fig. 4). In view of the elevated
mRNA levels in this range, reduced FMRP expression
is likely to reflect a translation defect that is beginning
even in the premutation range. A translation defect has
been reported in fibroblast cell lines (derived from one
male with mosaicism) in the full-mutation range (Feng
et al. 1995b).
The mechanistic basis for the elevated mRNA levels
in carrier males is not understood at present. At the most
basic level, such elevations could be the result of either
increased transcriptional activity of the FMR1 gene or
greater stability of the message itself (reduced rate of
loss) or both. Elevated levels of mRNA have been re-
ported for the myotonic dystrophy protein kinase gene
(DMPK) of myotonic dystrophy, another trinucleotide-
repeat–expansion disease that involves a CTG expansion
in the 3′ UTR region (Sabourin et al. 1993), although
this issue is controversial (Waring and Korneluk 1998,
pp. 131–146). We have examined the question of mRNA
stability, by measurement of the rates of decay of FMR1
mRNA in a lymphoblastoid cell line (160 CGG repeats)
derived from a carrier male (183 CGG repeats) and from
a normal control. That the decay half-lives for the nor-
mal and premutation lines are nearly equal (table 3)
indicates that altered (increased) stability cannot account
for the increased steady-state level of the FMR1 mRNA.
The absence of a significant increase in stability of the
FMR1 mRNA suggests that transcriptional activity of
the FMR1 gene is increased in carrier males. This pos-
sibility is particularly intriguing in light of the reduced
number of FMRP() lymphocytes in at least some car-
rier males with large premutation alleles (see fig. 4). If
defective translation of the FMR1 mRNA is occurring
for premutation alleles, then an early manifestation of
reduced translational efficiency may be feedback induc-
tion of the FMR1 gene, in an attempt to overcome a
mild protein deficit. Thus, normal or near-normal pro-
tein levels in the high-premutation range may only be
maintained through abnormally high levels of message,
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although no direct evidence for such a model currently
exists.
In the presentation of our results, we have intro-
duced a somewhat arbitrary division—at 100 CGG
repeats—between two groups of carrier males. This
distinction was introduced simply to illustrate the
trend in message level. We have also performed first-
order through third-order regression analyses of all
data in figure 2. These three analyses yielded similar
outcomes—namely, (a) relative mRNA levels that, for
alleles of 200 repeats, are eightfold higher than the
levels for alleles of 30 repeats and (b) coefficients of
determination that are comparable ( 2 2r = .76; r =1st 2d
). Thus, the current division yields a2.76; r = .783d
more conservative, model-free estimate for the degree
of elevation, and it is, in any case, more appropriate
in the absence of any underlying mechanism.
Finally, we wish to emphasize the utility of the fluo-
rescence-based RT-PCR approach. Real-time measure-
ments obtained throughout the PCR process enable one
to define a range of cycle numbers in which the response
of the fluorescent signal is linearly proportional to the
original concentration of RNA. This feature greatly im-
proves both precision and accuracy of the determination
of relative mRNA levels. In addition, the current inves-
tigation involved 11,000 individual PCR reactions for
full quantification of relative mRNA levels (concentra-
tion-dependence, secondary corrections, repetitions,
etc.); such numbers of PCR reactions are facilitated by
the relative ease of the automated measurements.
Acknowledgments
This work was supported by funding (to P.J.H. and R.J.H.)
from the Boory Family Fund and the Mulvey Family Fund, a
FRAXA Research Foundation Fellowship (to F.T.), National
Institutes of Health grants GM35305 (to P.J.H.) and HD36071
(to R.J.H.), and Maternal Child Health Bureau grant MCJ-
089413 (to R.J.H.). The authors wish to thank Janine Mills
for her help with oligonucleotide preparation.
Electronic-Database Information
Accession numbers and URLs for data in this article are as
follows:
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/Genbank
Overview.html (for FMR1 gene [accession number L29074]
and reference gene derived from GUS mRNA [accession
number NM000181]
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for fragile-X syndrome [MIM
309550])
References
Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D, Holden
JJ, Yang KT, Lee C, Hudson R, et al (1999) Fragile X pre-
mutation is a significant risk factor for premature ovarian
failure: the International Collaborative POF in Fragile X
study—preliminary data. Am J Med Genet 83:322–325
Baeyens DA, Cornett LE (1993) Transcriptional and posttran-
scriptional regulation of hepatic beta 2-adrenergic receptor
gene expression during development. J Cell Physiol 157:70–
76
Brown WT, Houck GE Jr, Jeziorowska A, Levinson FN, Ding
X, Dobkin C, Zhong N, et al (1993) Rapid fragile X carrier
screening and prenatal diagnosis using a nonradioactive
PCR test. JAMA 270:1569–1575
de Vries BBA, Jansen CCAM, Duits AA, Verheij C, Willemsen
R, van Hemel JO, van den Ouweland AMW, et al (1996)
Variable FMR1 gene methylation of large expansions leads
to variable phenotype in three males from one fragile X
family. J Med Genet 33:1007–1010
Devys D, Lutz Y, Rouyer N, Bellocq J-P, Mandel J-L (1993)
The FMR-1 protein is cytoplasmic, most abundant in neu-
rons and appears normal in carriers of a fragile X premu-
tation. Nat Genet 4:335–340
Dorn MB, Mazzocco MMM, Hagerman RJ (1994) Behavioral
and psychiatric disorders in adult male carriers of fragile X.
J Am Acad Child Adolesc Psychiatry 33:256–264
Feng Y, Lakkis L, Devys D, Warren ST (1995a) Quantitative
comparison of FMR1 gene expression in normal and pre-
mutation alleles. Am J Hum Genet 56:106–113
Feng Y, Zhang F, Lokey LK, Chastain JL, Lakkis L, Eberhart
D, Warren ST (1995b) Translational suppression by trinu-
cleotide repeat expansion at FMR1. Science 268:731–734
Franke P, Leboyer M, Gansicke M, Weiffenbach O, Biancalana
V, Cornillet-Lefebre P, Croquette MF, et al (1998) Genotype-
phenotype relationship in female carriers of the premutation
and full mutation of FMR-1. Psychiatry Res 80:113–127
Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, Richards
S, Verkerk AJ, et al (1991) Variation of the CGG repeat at
the fragile X site results in genetic instability: resolution of
the Sherman paradox. Cell 67:1047–1058
Gibson UE, Heid CA, Williams PM (1996) A novel method
for real time quantitative RT-PCR. Genome Res 6:995–1001
Gu Yanghong, Lugenbeel KA, Vockley JG, Grody WW, Nelson
DL (1994) A de novo deletion in FMR1 in a patient with
developmental delay. Hum Mol Genet 3:1705–1706
Hagerman RJ (1996) Physical and behavioral phenotype. In:
Hagerman RJ, Cronister AC (eds) Fragile X syndrome: di-
agnosis, treatment, and research, 2d ed. Johns Hopkins Uni-
versity Press, Baltimore, pp 3–87
——— (1999) Fragile X syndrome. In: Neurodevelopmental
disorders: diagnosis and treatment. Oxford University Press,
Oxford, pp 61–132
Hagerman RJ, Staley LW, O’Conner R, Lugenbeel K, Nelson
D, McLean SD, Taylor AK (1996) Learning-disabled males
with a fragile X CGG expansion in the upper premutation
size range. Pediatrics 97:122–126
Heid CA, Stevens J, Livak KJ, Williams PM (1996) Real time
quantitative PCR. Genome Res 6:986–994
Hmadcha A, De Diego Y, Pintado E (1998) Assessment of
Tassone et al.: Increased mRNA in Fragile-X Carriers 15
FMR1 expression by reverse transcriptase-polymerase chain
reaction of KH domains. J Lab Clin Med 131:170–173
Kaufmann WE, Abrams MT, Chen W, Reiss AL (1999) Ge-
notype, molecular phenotype, and cognitive phenotype: cor-
relations in fragile X syndrome. Am J Med Genet 83:286–
295
Livak KJ, Flood SJ, Marmaro J, Giusti W, Deetz K (1995)
Oligonucleotides with fluorescent dyes at opposite ends pro-
vide a quenched probe system useful for detecting PCR prod-
uct and nucleic acid hybridization. PCR Methods Appl 4:
357–362
Loesch DZ, Hay DA, Mulley J (1994) Transmitting males and
carrier females in fragile X—revisited. Am J Med Genet 51:
392–399
Loesch DZ, Hay DA, Sutherland GR, Halliday J, Judge C,
Webb GC (1987) Phenotypic variation in male-transmitted
fragile X: genetic inferences. Am J Med Genet 27:401–417
Mazzocco MM, Pennington BF, Hagerman RJ (1993) The neu-
rocognitive phenotype of female carriers of fragile X: ad-
ditional evidence for specificity. J Dev Behav Pediatr 14:328–
335
Murray A, Webb J, Grimley S, Conway G, Jacobs P (1998)
Studies of FRAXA and FRAXE in women with premature
ovarian failure. J Med Genet 35:637–640
Oberle` I, Rousseau F, Heitz D, Kretz C, Devys D, Hanauer A,
Boue` J, et al (1991) Instability of a 550–base pair DNA
segment and abnormal methylation in fragile X syndrome.
Science 252:1097–1102
Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey
CT, Nelson DL (1991) Absence of expression of the FMR-
1 gene in fragile X syndrome. Cell 66:817–822
Reiss AL, Freund L, Abrams MT, Boehm C, Kazazian H (1993)
Neurobehavioral effects of the fragile X premutation in adult
women: a controlled study. Am J Hum Genet 52:884–894
Riddle JE, Cheema A, Sobesky WE, Gardner SC, Taylor AK,
Pennington BF, Hagerman RJ (1998) Phenotypic involve-
ment in females with the FMR1 gene mutation. Am J Ment
Retard 102:590–601
Rousseau F, Heitz D, Tarleton J, MacPherson J, Malmgren H,
Dahl N, Barnicoat A, et al (1994) A multicenter study on
genotype-phenotype correlations in the fragile X syndrome,
using direct diagnosis with probe StB12.3: the first 2,253
cases. Am J Hum Genet 55:225–237
Sabourin LA, Mahadevan MS, Narang M, Lee DSC, Surh LC,
Korneluk RG (1993) Effect of the myotonic dystrophy (DM)
mutation on mRNA levels of the DM gene. Nat Genet 4:
233–238
Smeets HJM, Smits APT, Verheij CE, Theelen JPG, Willemsen
R, van de Burgt I, Hoogeveen AT, et al (1995) Normal phe-
notype in two brothers with a full FMR1 mutation. Hum
Mol Genet 4:2103–2108
Smits A, Smeets D, Hamel B, Dreesen J, de Haan A, van Oost
B (1994) Prediction of mental status in carriers of the fragile
X mutation using CGG repeat length. Am J Med Genet 51:
497–500
Steyaert J, Borghgraef M, Legius E, Fryns J-P (1996) Molec-
ular-intelligence correlations in young fragile X males with
a mild CGG repeat expansion in the FMR1 gene. Am J Med
Genet 64:274–277
Tassone F, Hagerman RJ, Ilke DN, Dyer PN, Lampe M, Wil-
lemsen R, Oostra BA, et al (1999) FMRP expression as a
potential prognostic indicator in fragile X syndrome. Am J
Med Genet 84:250–261
Tassone F, Hagerman RJ, Taylor AK, Mills JB, Wood S, Gane
LW, Hagerman PJ. Clinical involvement and protein ex-
pression in individuals with the FMR1 premutation. Am J
Med Genet (in press)
Taylor AK, Safanda JF, Fall MZ, Quince C, Lang KA, Hull
CE, Carpenter I, et al (1994) Molecular predictors of cog-
nitive involvement in female carriers of fragile X syndrome.
JAMA 271:507–514
Turner G, Robinson H, Wake S, Martin N (1994) Dizygous
twinning and premature menopause in fragile X syndrome.
Lancet 344:1500
Verheij C, Bakker CE, de Graaff E, Keulemans J, Willemsen
R, Verkerk AJ, Galjaard H, et al (1993) Characterization
and localization of the FMR-1 gene product associated with
fragile X syndrome. Nature 363:722–724
Waring JD, Korneluk RG (1998) Genetic studies of the my-
otonic dystrophy CTG repeat. In: Wells RD, Warren ST (eds)
Genetic instabilities and hereditary neurological diseases.
Academic Press, San Diego
Willemsen R, Mohkamsing S, de Vries BBA, Devys D, van den
Ouweland A, Mandel J-L, Galjaard H, et al (1995) Rapid
antibody test for fragile X syndrome. Lancet 345:1147–
1148
Willemsen R, Smits A, Mohkamsing S, van Beerendonk H, de
Haan A, de Vries B, van den Ouweland A, et al (1997) Rapid
antibody test for diagnosing fragile X syndrome: a validation
of the technique. Hum Genet 99:308–311
